Results 241 to 250 of about 4,142,440 (303)

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease

Epilepsia, EarlyView.
Abstract Background and Objective Lafora disease (LD) is a rare progressive disorder caused by mutations in the EPM2A or EPM2B genes, characterized by the accumulation of Lafora bodies, drug‐resistant epilepsy, and cognitive decline. To investigate the early molecular mechanisms of LD, we studied electrophysiological changes in the dentate gyrus (DG ...
Cinzia Costa, Laura Bellingacci, Jacopo Canonichesi, Valentina Imperatore, Anna Aurora Taddei, Luis Zafra‐Puerta, Nerea Iglesias‐Cabeza, Paolo Prontera, Andrea Mancini, Massimiliano Di Filippo, Alessandro Tozzi, Katiuscia Martinello, Marta Barzasi, Fabrizio Gardoni, Marina P. Sánchez, José M. Serratosa, Lucilla Parnetti, Miriam Sciaccaluga   +17 more
wiley   +1 more source

The Natural History of Marijuana Use Among Young Adult Medical Marijuana Patients in Los Angeles

, 2018
Avat Kioumarsi, Avat Kioumarsi, Stephen Lankenau   +2 more
openalex   +1 more source

Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the prevalence, frequency, and characteristics of headache disorders in transgender individuals receiving gender‐affirming hormone therapy (GAHT), and to explore the relationship between GAHT and headache pathophysiology.
Lucia Jimena Zavala, Andreina Gil Ramirez, Kjersti Grøtta Vetvik, Rigmor Højland Jensen, Anders Hougaard   +4 more
wiley   +1 more source

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani, Larry Charleston IV, Shannon Strom, Detlef Albrecht, Robert Cowan   +4 more
wiley   +1 more source

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the efficacy of cannabis for the treatment of acute migraine. Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.
Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton   +6 more
wiley   +1 more source